Search results for " and neonatal diseases and abnormalities"

showing 10 items of 344 documents

Bleomycin Exerts Ambivalent Antitumor Immune Effect by Triggering Both Immunogenic Cell Death and Proliferation of Regulatory T Cells

2013

International audience; Bleomycin (BLM) is an anticancer drug currently used for the treatment of testis cancer and Hodgkin lymphoma. This drug triggers cancer cell death via its capacity to generate radical oxygen species (ROS). However, the putative contribution of anticancer immune responses to the efficacy of BLM has not been evaluated. We make here the observation that BLM induces immunogenic cell death. In particular, BLM is able to induce ROS-mediated reticulum stress and autophagy, which result in the surface exposure of chaperones, including calreticulin and ERp57, and liberation of HMBG1 and ATP. BLM induces anti-tumor immunity which relies on calreticulin, CD8(+) T cells and inte…

MouseCancer TreatmentCD8-Positive T-LymphocytesT-Lymphocytes RegulatoryHematologic Cancers and Related DisordersMice0302 clinical medicineTransforming Growth Factor beta[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyCytotoxic T cellImmune Response0303 health sciencesMultidisciplinaryCell DeathbiologyQRFOXP3Animal ModelsHematology3. Good healthCell biologyOncology030220 oncology & carcinogenesisMedicine[SDV.IMM]Life Sciences [q-bio]/ImmunologyImmunogenic cell deathFemaleLymphomasOncology AgentsResearch ArticleTumor Immunologycongenital hereditary and neonatal diseases and abnormalitiesProgrammed cell death[SDV.IMM] Life Sciences [q-bio]/ImmunologyScienceImmunologyAntineoplastic Agentschemical and pharmacologic phenomenaBleomycin03 medical and health sciencesModel OrganismsImmune systemCell Line TumorAnimalsHumansBiologyCell Proliferation030304 developmental biologyHodgkin Lymphomaurogenital systemCell growthImmunitynutritional and metabolic diseasesImmunologic SubspecialtiesChemotherapy and Drug TreatmentImmunity InnateCancer cellbiology.proteinClinical ImmunologyCalreticulinPLoS ONE
researchProduct

ROP, the Drosophila Sec1 homolog, interacts with syntaxin and regulates neurotransmitter release in a dosage-dependent manner.

1998

The Sec1 family of proteins is thought to function in both non-neuronal and neuronal secretion, although the precise role of this protein family has not been defined. Here, we study the function of ROP, the Drosophila Sec1 homolog, in neurotransmitter release. Electrophysiological analyses of transgenic lines overexpressing ROP and syntaxin, a presynaptic membrane protein, indicate that ROP interacts with syntaxin in vivo. Characterization of four point mutations in ROP shows that they fall into two phenotypic classes. Two mutations cause a dramatic reduction in both evoked and spontaneous neurotransmitter release. In contrast, the other two mutations reveal an increase in evoked neurotrans…

Munc18 Proteinscongenital hereditary and neonatal diseases and abnormalitiesProtein familyNerve Tissue ProteinsNeurotransmissionBiologySynaptic TransmissionGeneral Biochemistry Genetics and Molecular BiologySyntaxin bindingExocytosischemistry.chemical_compoundSyntaxinAnimalsDrosophila ProteinsNeurotransmitterMolecular BiologyNeurotransmitter AgentsGeneral Immunology and MicrobiologyQa-SNARE ProteinsGeneral NeuroscienceMembrane ProteinsSyntaxin 3eye diseasesCell biologychemistryDrosophilaResearch ArticleThe EMBO journal
researchProduct

Clinical, pathologic, and genetic features of massive soft tissue neurofibromas in a Sicilian patient

2008

Abstract CONTEXT: Lipase maturation factor 1 (LMF1) gene is a novel candidate gene in severe hypertriglyceridemia. Lmf1 is involved in the maturation of lipoprotein lipase (LPL) and hepatic lipase in endoplasmic reticulum. To date only one patient with severe hypertriglyceridemia and related disorders was found to be homozygous for a nonsense mutation in LMF1 gene (Y439X). OBJECTIVE: The objective of the study was to investigate LMF1 gene in hypertriglyceridemic patients in whom mutations in LPL, APOC2, and APOA5 genes had been excluded. RESULTS: The resequencing of LMF1 gene led to the discovery of a novel homozygous nonsense mutation in one patient with severe hypertriglyceridemia and rec…

Nonsynonymous substitutionMalecongenital hereditary and neonatal diseases and abnormalitiesPathologymedicine.medical_specialtyHeterozygoteNeurofibromatosis 1BiopsyDNA Mutational AnalysisMutation MissenseSoft Tissue NeoplasmsDermatologymassive soft tissue neurofibromas NeurofibromatosisBiologymedicine.disease_causeFrameshift mutationExonGenes Neurofibromatosis 1medicineSettore MED/35 - Malattie Cutanee E VenereeMissense mutationHumansNeurofibromatosisFrameshift MutationGeneSicilyGeneticsMutationHeterozygote advantageGeneral MedicineExonsMiddle Agedmedicine.diseasenervous system diseasesGene Expression Regulation NeoplasticButtocks
researchProduct

Measurement of the background in the NEMO 3 double beta decay experiment

2009

In the double beta decay experiment NEMO 3 a precise knowledge of the background in the signal region is of outstanding importance. This article presents the methods used in NEMO 3 to evaluate the backgrounds resulting from most if not all possible origins. It also illustrates the power of the combined tracking-calorimetry technique used in the experiment.

Nuclear and High Energy Physicscongenital hereditary and neonatal diseases and abnormalitiesSignal regionchemistry.chemical_elementFOS: Physical sciencesRadon[PHYS.NEXP]Physics [physics]/Nuclear Experiment [nucl-ex]01 natural sciencesNuclear physicsNEMODouble beta decay0103 physical sciencesNeutrino Ettore Majorana ObservatoryNuclear Experiment (nucl-ex)010306 general physicsskin and connective tissue diseasesLow radioactivityInstrumentationNuclear ExperimentPhysics010308 nuclear & particles physicsDetectorDouble beta decayPower (physics)BackgroundchemistryRadon
researchProduct

Breast-cancer predisposition in multiple endocrine neoplasia type 1

2014

Women with multiple endocrine neoplasia type 1 related to mutations in the gene encoding menin (MEN1) have approximately twice the risk of breast cancer as do women in the general population.

OncologyAdultRiskcongenital hereditary and neonatal diseases and abnormalitiesendocrine systemmedicine.medical_specialtyendocrine system diseasesGenotypePopulationVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Breast Neoplasmsmedicine.disease_causeArticleBreast cancerSDG 3 - Good Health and Well-beingInternal medicineProto-Oncogene ProteinsGenotypemedicineCarcinomaMultiple Endocrine Neoplasia Type 1HumansMEN1Genetic Predisposition to DiseaseLongitudinal StudiesMultiple endocrine neoplasiaeducationGeneralLiterature_REFERENCE(e.g.dictionariesencyclopediasglossaries)GeneNetherlandsMutationeducation.field_of_studybusiness.industryCarcinoma Ductal BreastGeneral MedicineMiddle Agedmedicine.diseaseCarcinoma PapillaryImmunologyMutationFemalebusiness
researchProduct

Correction:Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrom…

2020

Lynch syndrome (LS) results from pathogenic variants in the mismatch repair (MMR) genes and is the most common hereditary cancer syndrome, affecting an estimated 1 in 300 individuals. Pathogenic variants in each of the MMR genes path_MLH1, path_MSH2, path_MSH6, and path_PMS2 result in different risks for cancers in organs including the colorectum, endometrium, ovaries, stomach, small bowel, bile duct, pancreas, and upper urinary tract. Accurate estimates of these risks are essential for planning appropriate approaches to the prevention or early diagnosis of cancers but the robustness of previous studies has been limited by factors including retrospective design,1,2 lack of validation in ind…

OncologyMaleColorectal cancer*Lynch syndromePenetranceDNA Mismatch Repair0302 clinical medicineDatabases GeneticMalalties hereditàriesProspective StudiesCàncer*PMS2Genetics (clinical)Mismatch Repair Endonuclease PMS2Cancer0303 health sciencesSex CharacteristicsFactors de risc en les malalties1184 Genetics developmental biology physiologyMLH1Middle Aged16. Peace & justiceLynch syndrome3. Good healthDNA-Binding ProteinsMutS Homolog 2 Proteinsyöpägeenit*MSH2030220 oncology & carcinogenesis*MSH6030211 gastroenterology & hepatologyDNA mismatch repairFemalegeneettiset tekijätMutL Protein Homolog 1Genetic diseasesAdultmedicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiesRisk factors in diseasessuolistosyövätMUTATION CARRIERSMLH1Risk AssessmentArticlesukupuoliAge and gender03 medical and health sciencesInternal medicinemedicineHumansGenetic Predisposition to DiseaseLynchin oireyhtymäGene030304 developmental biologyAgedbusiness.industryEndometrial cancerCorrectionnutritional and metabolic diseasesCancer*MLH1MSH6medicine.diseaseColorectal Neoplasms Hereditary NonpolyposisSurvival Analysisdigestive system diseasesMSH2MSH6Lynch syndromePMS2MSH2Mutation3111 BiomedicineikäbusinessOvarian cancer
researchProduct

Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer.

2021

To evaluate the cost-effectiveness of first-line treatments, such as erlotinib, gefitinib, afatinib, dacomitinib, and osimertinib, for patients diagnosed with stage IIIB/IV NSCLC harboring EGFR mutations.A partitioned survival model was developed to estimate quality-adjusted life-year (QALY) and incremental cost-effectiveness ratio (ICER) from the perspective of the Spanish National Health System. Two Bayesian NMAs were performed independently, by using the polynomial fraction method to fit Kaplan-Meier curves for overall survival and progression-free survival. Deterministic and probabilistic sensitivity analyses were performed to evaluate the uncertainty.The ICER was calculated for the fou…

Oncologycongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyLung NeoplasmsCost effectivenessAfatinibCost-Benefit AnalysisAfatinibchemistry.chemical_compoundErlotinib HydrochlorideGefitinibInternal medicineCarcinoma Non-Small-Cell LungmedicineHumansheterocyclic compoundsPharmacology (medical)OsimertinibLung cancerneoplasmsProtein Kinase Inhibitorsbusiness.industryHealth PolicyBayes TheoremGefitinibGeneral MedicineCost-effectiveness analysismedicine.diseaseDacomitinibrespiratory tract diseasesErbB ReceptorschemistryMutationErlotinibbusinessmedicine.drugExpert review of pharmacoeconomicsoutcomes research
researchProduct

Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2).

2022

Abstract Antibody therapeutics can be associated with unwanted immune responses resulting in the development of anti‐drug antibodies (ADA). Optimal methods to evaluate the potential effects of ADA on clinical outcomes in oncology are not well established. In this study, we assessed efficacy and safety, based on ADA status, in patients from over 10 clinical trials that evaluated the immune checkpoint inhibitor atezolizumab as a single agent or as combination therapy for several types of advanced cancers. ADA can only be observed post randomization, and imbalances in baseline prognostic factors can confound the interpretation of ADA impact. We applied methodology to account for the confoundin…

Oncologymedicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiesRandomizationCombination therapyDatabases FactualMEDLINERM1-950Antibodies Monoclonal HumanizedGeneral Biochemistry Genetics and Molecular BiologyArticleAtezolizumabimmune system diseasesInternal medicineNeoplasmsmedicineHumansGeneral Pharmacology Toxicology and PharmaceuticsAdverse effectImmune Checkpoint InhibitorsClinical Trials as Topicbusiness.industryGeneral NeuroscienceImmunogenicityResearchConfoundingnutritional and metabolic diseaseshemic and immune systemsGeneral MedicineArticlesAntibodies Monoclonal Humanized/immunology; Antibodies Monoclonal Humanized/pharmacokinetics; Antibodies Neutralizing/immunology; Antibodies Neutralizing/metabolism; Clinical Trials as Topic; Databases Factual; Humans; Immune Checkpoint Inhibitors/immunology; Immune Checkpoint Inhibitors/pharmacokinetics; Neoplasms/drug therapy; Safety; Treatment OutcomeAntibodies NeutralizingClinical trialenzymes and coenzymes (carbohydrates)Treatment OutcomeTherapeutics. PharmacologyPublic aspects of medicineRA1-1270SafetybusinessClinical and translational science
researchProduct

Niemann-Pick Type C-2 Disease: Identification by Analysis of Plasma Cholestane-3β,5α,6β-Triol and Further Insight into the Clinical Phenotype.

2014

Niemann-Pick type C disease is a rare disorder caused by impaired intracellular lipid transport due to mutations in either the NPC1 or the NPC2 gene. Ninety-five % of NPC patients show mutations in the NPC1 gene. A much smaller number of patients suffer from NPC2 disease and present respiratory failure as one of the most frequent symptoms. Several plasma oxysterols are highly elevated in NPC1 and can be used as a biomarker in the diagnosis of NPC1.Plasma cholestane-3β,5α,6β-triol was evaluated as biomarker for NPC2 by GC/MS and LC-MS/MS analysis. The diagnosis was confirmed by Sanger sequencing and filipin staining.We report three NPC2 patients with typical respiratory problems and a detail…

Pathologymedicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiesbusiness.industrynutritional and metabolic diseasesDiseaseIntracellular lipid transportmedicine.diseaseArticlenervous system diseasesRespiratory failurehemic and lymphatic diseasesImmunologyMedicineCholestane 3β 5α 6β triolBiomarker (medicine)lipids (amino acids peptides and proteins)NPC1businessPulmonary alveolar proteinosisGeneJIMD reports
researchProduct

Opsoclonus-myoclonus syndrome attributable to West Nile encephalitis: a case report

2014

Introduction Opsoclonus-myoclonus syndrome is a very rare neurological disorder associated with some viral infections and exceptionally with the West Nile virus. Case presentation A 57-year-old Caucasian woman presented with fever, dizziness, balance difficulties, vomiting, dancing eye, altered speech, tremor, generalized myoclonus and failure to rise or stand. Our objective is to describe a patient with West Nile infection, which was identified both in her serum and cerebrospinal fluid and was associated with encephalitis and opsoclonus-myoclonus-ataxia syndrome. Conclusions Opsoclonus-myoclonus-ataxia syndrome continued for 4 weeks after onset, when she died. There was no evidence for any…

Pediatricsmedicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiesWest Nile virusCase ReportNeurological disordermedicine.disease_causeAntibodies ViralOpsoclonus myoclonus syndromemental disordersmedicineHumansMedicine(all)Opsoclonus-Myoclonus Syndromebusiness.industryGeneral MedicineWest Nile encephalitisMiddle Agedmedicine.diseasenervous system diseasesImmunologyVomitingEtiologyEncephalitisFemalemedicine.symptombusinessMyoclonusWest Nile virusEncephalitisWest Nile FeverJournal of Medical Case Reports
researchProduct